Sandoz gains rights to Graftskin:
This article was originally published in Clinica
Organogenesis has granted Swiss pharmaceutical company Sandoz the licensing rights to Graftskin, its manufactured human skin product. Under the terms of the agreement, Sandoz will have exclusive worldwide rights to the product and will pay Organogenesis $37.5 million in equity investments, milestone payments and research support. The initial equity investment of $5 million will give Sandoz 1.6% of the outstanding shares of Massachusetts-based Organogenesis. Graftskin's PMA for venous stasis ulcers has been granted expedited review status by the US FDA.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.